Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Depreciation and Depletion (2017 - 2025)

Cue Biopharma's Depreciation and Depletion history spans 9 years, with the latest figure at $76000.0 for Q3 2025.

  • For Q3 2025, Depreciation and Depletion fell 21.65% year-over-year to $76000.0; the TTM value through Sep 2025 reached $355000.0, down 17.82%, while the annual FY2024 figure was $385000.0, 29.36% down from the prior year.
  • Depreciation and Depletion for Q3 2025 was $76000.0 at Cue Biopharma, down from $97000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $232000.0 in Q3 2021 and bottomed at $76000.0 in Q3 2025.
  • The 5-year median for Depreciation and Depletion is $139000.0 (2023), against an average of $154321.8.
  • The largest annual shift saw Depreciation and Depletion rose 23.08% in 2021 before it plummeted 49.49% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $227114.0 in 2021, then fell by 11.5% to $201000.0 in 2022, then tumbled by 30.85% to $139000.0 in 2023, then crashed by 38.85% to $85000.0 in 2024, then decreased by 10.59% to $76000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Depreciation and Depletion are $76000.0 (Q3 2025), $97000.0 (Q2 2025), and $97000.0 (Q1 2025).